THE EVOLUTION OF CANCER IMMUNOTHERAPY


ABOUT

Turnstone Biologics is driven by science and innovation, with experienced leadership and world-renowned scientific founders in the field of oncolytics and immunotherapies

The Technology

A first-in-class oncolytic viral immunotherapy that combines a bioselected and engineered oncolytic virus to directly lyse tumors with a potent vaccine technology to drive tumor-antigen specific T-cell responses of unprecedented magnitude.


The Advantage

Highly differentiated products that stimulate a patient’s immune response, specifically designed to overcome many shortcomings of other oncolytic therapies and generate large and durable adaptive immune responses.


The Promise

Currently executing Phase I/II study for lead program, and building foundation of high content clinical trials across multiple indications as standalone treatment and in combination with other immunotherapies.


TECHNOLOGY

The Foundation: Maraba is the Ideal Oncolytic Virus

The Maraba platform represents Turnstone’s lead oncolytic immunotherapy agent. Maraba was bioselected from rhabdovirus isolates from around the world as the most potent tumor lytic strain. The final product was developed through iterative genetic engineering of Maraba to maximize its inherent safety and potency profile. Highlights of the platform include: potent killing of most tumor cell types, highly attenuated in normal human cells, no pre-existing immunity, systemic administration and activity, and ease of manufacturing.

The direct cancer-killing properties of Turnstone’s oncolytic viral immunotherapy platform.

OVa_whiteframe-1024x606

The Evolution: Maraba is also the Ideal T Cell Vaccine

To complement the powerful tumor destructive properties of the Maraba oncolytic virus, Turnstone has further engineered Maraba to act as an incredibly effective T cell vaccine driving the immune system to target the tumor for destruction. This innovation is achieved by encoding tumor antigens into Maraba’s genetic code. When administered systemically, it triggers a massive amplification of T cell immune responses targeted to the antigens present on the tumor cells, and facilitates long-term immune recognition.

The immune boosting properties of Turnstone’s oncolytic viral immunotherapy platform

Technology-Graphic-2-e1452219187536

Currently in clinical development, this exciting new technology is able to focus the immune system on the antigen expressing tumors thereby enhancing oncolytic potency, tumor specificity, and overall sustained anti-cancer immune responses. The Maraba oncolytic viral immunotherapy platform is a vanguard technology representing a disruptive approach in the treatment of cancer.

LEADERSHIP

The Evolution of
Cancer Immunotherapy

Kris Elverum, BS, MBA

Chief Business Officer

[X]

Kris Elverum, BS, MBA

Chief Business Officer

Kris Elverum brings over 12 years of experience in corporate strategy, business development, commercial, and operations in pharmaceuticals and cell therapies to Turnstone Biologics Inc.  He joined Turnstone from his most recent position as Chief Business Officer of SQZ Biotech.  Previously, Kris led Novartis’ US commercial model for the breakthrough cell therapy CTL019 and other CAR T-cell immunotherapies, held various commercial roles for Novartis Pharmaceuticals, and was a corporate executive group member as the Global Head of Strategy for Sandoz.  Before that, he was an Engagement Manager with McKinsey & Co. where he served clients across the health care value chain.  Kris holds an MBA and BS from the University of Minnesota’s Carlson School of Management.

Brian Lichty, PhD

Chief Technology Officer

[X]

Brian Lichty, PhD

Chief Technology Officer

Dr. Brian Lichty is a distinguished scientist with extensive expertise in oncolytic viruses and related immunotherapies, including seminal work with Dr. John Bell at the Ottawa Regional Cancer Centre.  He has been a professor in the Department of Pathology & Molecular Medicine and the McMaster Immunology Research Centre (MIRC) at McMaster University since 2004.  Dr. Lichty’s expertise includes influence research in the identification of strategies to leverage oncolytic viruses to harness the patient’s immune system in a sustainable manner, including vaccine design and engineering to directly engage the adaptive immune system tumour-specific and/or to enhance combinations with other immunotherapies.  He is also director of the Robert E. Fitzhenry vector lab at McMaster where clinical grade viral vaccines are manufactured for human clinical trials.   Dr. Brian Lichty received his PhD from the University of Toronto and holds a BSc from the University of Guelph.

Sammy Farah, PhD, MBA

President and Chief Executive Officer

[X]

Sammy Farah, PhD, MBA

President and Chief Executive Officer

Dr. Sammy Farah brings extensive vaccine expertise and almost 20 years of scientific, business and executive management experience in the biotechnology industry to Turnstone Biologics Inc. He came to Turnstone from his most recent position as President of Synthetic Genomics Vaccines, Inc., and previous to that, Chief Business Officer of Immune Design Corp.  Prior to those roles, Sammy was at Versant Ventures where he specialized in biotechnology investing and new company formation; and at Merck & Co., Inc. where he led technology support for multiple commercial vaccine franchises before joining the business development and licensing group to evaluate and execute new external technology and research partnerships. Dr. Farah received his Masters of Business Administration from the Wharton School, University of Pennsylvania, a Ph.D in Biochemical Engineering from Stanford University and a Bachelor of Science degree in Biochemical Engineering from the Massachusetts Institute of Technology.

Caroline Breitbach, PhD

Vice President, Translational Development

[X]

Caroline Breitbach, PhD

Vice President, Translational Development

Dr. Caroline Breitbach comes to Turnstone Biologics from SillaJen Biotherapeutics (formerly Jennerex) where she was Vice President, Clinical & Translational Research. In this position she oversaw translational and early-stage clinical development of an oncolytic immunotherapy and contributed to lead candidate development from Phase 1 through initiation of Phase 3 testing. Caroline received her undergraduate degree, Honours in Microbiology & Immunology, at McGill University in Montreal, Canada. She subsequently joined Dr John Bell’s group at the University of Ottawa in Ottawa, Canada where she evaluated acute effects of oncolytic viruses on the tumour immune microenvironment.

Maura Campbell, PhD

Vice President, Corporate Affairs

[X]

Maura Campbell, PhD

Vice President, Corporate Affairs

Maura has spent over 20 years in technology transfer and the management and commercialization of intellectual property.  Maura has business management experience in all main sectors of biotech: private and public companies; universities and research institutes; and government funded public sector research organizations (National Centres of Excellence Program – NCE).  Maura comes to Turnstone Biologics from Nasdaq-listed VBI Vaccines where she has served as Director, Intellectual Property.  During the past 5 years Maura also was with the Ottawa Hospital Research Institute (OHRI) as a Senior Research Program Manager overseeing the Oncolytic Vaccine project commercialization.  Prior to these positions Maura was the Director of Intellectual Property with PainCeptor Pharma Corporation, Manager of Technology Transfer & Commercialization at the OHRI, Manager of Technology Transfer at the Institute for Robotics and Intelligent Systems NCE and has served as an IP consultant to a number of Canadian start-ups including Neurochem, Conjuchem, Aonix, AMRIC and Sussex Research Labs to name a few. Maura received her B.Sc. and M.Sc., in Biochemistry, at Queen’s University in Kingston and graduated with her Ph.D. in Biochemistry from the University of Ottawa.

Brian Lichty, PhD

[X]

Brian Lichty, PhD

Dr. Brian Lichty is a distinguished scientist with extensive expertise in oncolytic viruses and related immunotherapies, including seminal work with Dr. John Bell at the Ottawa Regional Cancer Centre.  He has been a professor in the Department of Pathology & Molecular Medicine and the McMaster Immunology Research Centre (MIRC) at McMaster University since 2004.  Dr. Lichty’s expertise includes influence research in the identification of strategies to leverage oncolytic viruses to harness the patient’s immune system in a sustainable manner, including vaccine design and engineering to directly engage the adaptive immune system tumour-specific and/or to enhance combinations with other immunotherapies.  He is also director of the Robert E. Fitzhenry vector lab at McMaster where clinical grade viral vaccines are manufactured for human clinical trials.   Dr. Brian Lichty received his PhD from the University of Toronto and holds a BSc from the University of Guelph.

John Bell, PhD

[X]

John Bell, PhD

Dr. John Bell received his PhD from McMaster University, then trained at the Medical Research Council in London, England. John began his independent research career at McGill University before moving to the University of Ottawa and becoming a Professor in the Department of Medicine.  He is a member of the Center for Innovative Cancer Therapeutics at The Ottawa Hospital Cancer Center and a Senior Scientist with the Ottawa Hospital Research Institute. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox funded group from across Canada that is developing virus based cancer therapeutics and is the Director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. John is the Scientific Director of the recently awarded National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and a Fellow of the Royal Society of Canada.

David Stojdl, PhD

[X]

David Stojdl, PhD

Dr. David Stojdl has pioneered the exploration of host-virus interactions critical to oncolytic therapy to guide the clinical development of more effective virus platforms. At the Ottawa Regional Cancer Centre, he first identified VSV as an oncolytic virus and defined the archetypal role of interferon signaling in tumour-specific oncolytic virus targeting. Since joining the CHEO Research Institute in 2004, Dr. Stojdl has discovered and developed several novel oncolytic vector platforms, including the Maraba oncolytic virus platform. Dr. Stojdl also directs the CHEO Automated Screening Centre (CASC), leveraging state-of-the-art high-throughput robotic screening technology to uncover new insights for the clinical development of oncolytic virus biotherapies. Dr. Stojdl is a professor in the Department of Pediatrics and Department of Biochemistry, Microbiology and Immunology at the University of Ottawa, and was a scientific co-founder and consultant to Jennerex Biotherapeutics (San Francisco, USA; later acquired by SillaJen Biotherapeutics). He obtained his Ph.D from the University of Ottawa, and earned Bachelors and Masters degrees in Microbiology and Immunology from the University of Western Ontario.

Sammy Farah, PhD, MBA

[X]

Sammy Farah, PhD, MBA

Dr. Sammy Farah brings extensive vaccine expertise and almost 20 years of scientific, business and executive management experience in the biotechnology industry to Turnstone Biologics Inc. He came to Turnstone from his most recent position as President of Synthetic Genomics Vaccines, Inc., and previous to that, Chief Business Officer of Immune Design Corp.  Prior to those roles, Sammy was at Versant Ventures where he specialized in biotechnology investing and new company formation; and at Merck & Co., Inc. where he led technology support for multiple commercial vaccine franchises before joining the business development and licensing group to evaluate and execute new external technology and research partnerships. Dr. Farah received his Masters of Business Administration from the Wharton School, University of Pennsylvania, a Ph.D in Biochemical Engineering from Stanford University and a Bachelor of Science degree in Biochemical Engineering from the Massachusetts Institute of Technology.

Jerel Davis, PhD

[X]

Jerel Davis, PhD

Dr. Jerel Davis is a Managing Director at Versant Ventures and is based in Vancouver. Since joining Versant in 2011, he has played a critical role in launching and investing in a number of Versant’s portfolio companies including Quanticel Pharmaceuticals, Crispr Therapeutics, Blueline Bioscience, Northern Biologics and several of the Inception Sciences discovery start-ups. He has also led Versant’s execution of build-to-buy structured acquisitions with Celgene, Roche and Bayer. Over the last few years, Jerel has focused on establishing Versant’s presence in Canada, including the launch of new companies in Vancouver, Toronto and Montreal. Prior to joining Versant, Jerel was Associate Principal at McKinsey and Company where he advised healthcare corporations in pharmaceuticals, biotechnology, medical device and molecular diagnostics. He has worked in a number of healthcare markets globally including the US, Europe, China, Russia and India. Jerel was a post doctoral researcher at Stanford University until 2005 and in research at Amgen from 1999-2000.

Brad Bolzon, PhD

[X]

Brad Bolzon, PhD

Dr. Brad Bolzon is a Managing Director who brings more than thirteen years of global pharmaceutical industry experience to Versant’s biotech investment team. He specializes in early-stage biotech investing with a particular emphasis on new company start-ups.  Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with F. Hoffmann-La Roche. Under his leadership, Roche established alliances with over 75 biotech companies worldwide and significantly strengthened its product pipeline. Previously, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs, and business development.

Jeff Courtney, BSc

[X]

Jeff Courtney, BSc

Mr. Jeff Courtney has extensive experience in venture capital, business development and strategic planning.  Prior to joining FACIT (Fight Against Cancer Innovation Trust), Mr. Courtney was Managing Director of Verde Ventures, a management consulting firm specializing in providing financial and strategic advice to companies in the life sciences, health care and technology. Mr. Courtney is Co-founder and CEO of Sempra Therapeutics, a dermatology startup company.  As General Partner at VG Partners, Mr. Courtney was part of the leadership team that oversaw the $250M Advanced Life Sciences Fund. Mr. Courtney also was a partner at CDP Sofinov, President of Faulding Canada Inc., Executive Vice-President of Pharmascience Inc. and held various senior positions with Johnson & Johnson. Mr. Courtney has served on numerous boards of directors for public and private enterprises in the biomedical industry and is currently a director on the boards of the Ontario Preclinical Imaging Consortium, Centre for Imaging Technology Commercialization, DLVR Therapeutics, XLV Diagnostics and Turnstone Biologics. He is a member of the Investment Committee of the MaRS Discovery District’s Investment Accelerator Fund.  Mr. Courtney holds a BSc in microbiology from the University of Guelph.

John Bell, Phd

[X]

John Bell, Phd

Dr. John Bell received his PhD from McMaster University, then trained at the Medical Research Council in London, England. John began his independent research career at McGill University before moving to the University of Ottawa and becoming a Professor in the Department of Medicine. He is a member of the Center for Innovative Cancer Therapeutics at The Ottawa Hospital Cancer Center and a Senior Scientist with the Ottawa Hospital Research Institute. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox funded group from across Canada that is developing virus based cancer therapeutics and is the Director of the Biotherapeutics Program for the Ontario Institute for Cancer Research. John is the Scientific Director of the recently awarded National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and a Fellow of the Royal Society of Canada.

Ben Auspitz, BA

[X]

Ben Auspitz, BA

Ben Auspitz is a Partner at F-Prime Capital, and has worked in pharmaceuticals and life-science for over twenty years, both in industry, as a consultant, and as an investor. Most recently before joining F-Prime Capital, he served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company. In this role, he oversaw the advancement of seven programs from assay stage into phase II clinical studies, and was co-inventor on 15 product patents. Ben focuses on therapeutics, with a particular interest in Series A and company formation — including first venture investments in Ultragenyx, REGENX Biosciences, Symbiomix Therapeutics, Precision Biosciences, Unum Therapeutics, and two companies where he was a company founder, Orchard Therapeutics and Dimension Therapeutics.

He currently serves on the Board of Directors of Unum Therapeutics, Precision Biosciences, Orchard Therapeutics, Symbiomix Pharmaceuticals, and Compass Therapeutics. Previously, Ben was involved in F-Prime Capital investments in Bikam Pharmaceuticals (acquired by Shire), Ligocyte Pharmaceuticals (acquired by Takeda), Respivert (acquired by Johnson and Johnson), Blueprint Medicine (NASDAQ: BPMC), Coherus Biosciences (NASDAQ: CHRS), REGENXBio (NASDAQ: RGNX), Dimension Therapeutics (NASDAQ:DMTX), and Ultragenyx (NASDAQ: RARE)

He holds a B.A. from Harvard University.

Rishi Gupta, BA, JD

[X]

Rishi Gupta, BA, JD

Rishi Gupta is a private equity partner at OrbiMed and has been with the firm since 2003. Prior to OrbiMed, he was a healthcare investment banker at Raymond James & Associates, served as manager of corporate development at Veritas Medicine and was a summer associate at Wachtell, Lipton, Rosen & Katz. Mr. Gupta has published scientific articles on the mechanisms of HIV entry into host cells and legal articles on intellectual property laws in the developing world. In addition to Turnstone, Mr. Gupta serves or has served on the boards of Dimension Therapeutics, Symbiomix Therapeutics, Avitide, Verona Pharma, ChemoCentryx, and Sientra. He has also been actively involved with OrbiMed’s investments in Acceleron Pharma, CoGenesys, Supernus Pharmaceuticals, Adimab, Receptos, Aragon Pharmaceuticals, Seragon Pharmaceuticals, Alector, Arsanis, Biotie, Invitae, and ORIC Pharmaceuticals. Mr. Gupta received his A.B. degree magna cum laude in biochemical sciences from Harvard College and holds a J.D. from the Yale Law School.

NEWS

 

PUBLICATIONS

CONTACT

787 Bank Street, 2nd Floor,
Ottawa, Ontario K1S 3V5

613-421-8930
info@turnstonebio.com

110 E 25th Street,
New York, New York 10010

613-421-8930
info@turnstonebio.com

CAREERS